Rotigotine transdermal delivery for the treatment of Parkinson's disease

Autores
Rascol, Olivier; Perez Lloret, Santiago
Año de publicación
2009
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Background: Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications. Objective: To consider the evidence surrounding the profile of rotigotine and, in particular, whether its constant delivery system offers significant benefits to the treatment of early and advanced PD. Methods: Source material was identified using a PubMed search for the term 'rotigotine' (up to March 2008). The review focuses only on publications related to the rotigotine indication for PD. Results/conclusion: The rotigotine transdermal patch demonstrates clinical efficacy, alongside a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists. The once-daily patch formulation may favour compliance but, in similarity with the other theoretical advantages of constant drug delivery (for example reduced emergence of motor complications, improved tolerance to peripheral AEs), requires further detailed study.
Fil: Rascol, Olivier. Inserm; Francia
Fil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
Materia
CONTINUOUS DELIVERY SYSTEM (CDS)
DOPAMINE AGONIST
LEVODOPA
MOTOR FLUCTUATIONS
PARKINSON'S DISEASE
ROTIGOTINE
TRANSDERMAL PATCH
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/114178
Acceder
id CONICETDig_8f40141c2a10a0859b56a91db4e39413
oai_identifier_str oai:ri.conicet.gov.ar:11336/114178
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Rotigotine transdermal delivery for the treatment of Parkinson's diseaseRascol, OlivierPerez Lloret, SantiagoCONTINUOUS DELIVERY SYSTEM (CDS)DOPAMINE AGONISTLEVODOPAMOTOR FLUCTUATIONSPARKINSON'S DISEASEROTIGOTINETRANSDERMAL PATCHhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Background: Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications. Objective: To consider the evidence surrounding the profile of rotigotine and, in particular, whether its constant delivery system offers significant benefits to the treatment of early and advanced PD. Methods: Source material was identified using a PubMed search for the term 'rotigotine' (up to March 2008). The review focuses only on publications related to the rotigotine indication for PD. Results/conclusion: The rotigotine transdermal patch demonstrates clinical efficacy, alongside a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists. The once-daily patch formulation may favour compliance but, in similarity with the other theoretical advantages of constant drug delivery (for example reduced emergence of motor complications, improved tolerance to peripheral AEs), requires further detailed study.Fil: Rascol, Olivier. Inserm; FranciaFil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; ArgentinaInforma Healthcare2009-03info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/114178Rascol, Olivier; Perez Lloret, Santiago; Rotigotine transdermal delivery for the treatment of Parkinson's disease; Informa Healthcare; Expert Opinion on Pharmacotherapy; 10; 4; 3-2009; 677-6911465-6566CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14656560902746041info:eu-repo/semantics/altIdentifier/doi/10.1517/14656560902746041info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:52:11Zoai:ri.conicet.gov.ar:11336/114178instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:52:12.128CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Rotigotine transdermal delivery for the treatment of Parkinson's disease
title Rotigotine transdermal delivery for the treatment of Parkinson's disease
spellingShingle Rotigotine transdermal delivery for the treatment of Parkinson's disease
Rascol, Olivier
CONTINUOUS DELIVERY SYSTEM (CDS)
DOPAMINE AGONIST
LEVODOPA
MOTOR FLUCTUATIONS
PARKINSON'S DISEASE
ROTIGOTINE
TRANSDERMAL PATCH
title_short Rotigotine transdermal delivery for the treatment of Parkinson's disease
title_full Rotigotine transdermal delivery for the treatment of Parkinson's disease
title_fullStr Rotigotine transdermal delivery for the treatment of Parkinson's disease
title_full_unstemmed Rotigotine transdermal delivery for the treatment of Parkinson's disease
title_sort Rotigotine transdermal delivery for the treatment of Parkinson's disease
dc.creator.none.fl_str_mv Rascol, Olivier
Perez Lloret, Santiago
author Rascol, Olivier
author_facet Rascol, Olivier
Perez Lloret, Santiago
author_role author
author2 Perez Lloret, Santiago
author2_role author
dc.subject.none.fl_str_mv CONTINUOUS DELIVERY SYSTEM (CDS)
DOPAMINE AGONIST
LEVODOPA
MOTOR FLUCTUATIONS
PARKINSON'S DISEASE
ROTIGOTINE
TRANSDERMAL PATCH
topic CONTINUOUS DELIVERY SYSTEM (CDS)
DOPAMINE AGONIST
LEVODOPA
MOTOR FLUCTUATIONS
PARKINSON'S DISEASE
ROTIGOTINE
TRANSDERMAL PATCH
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Background: Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications. Objective: To consider the evidence surrounding the profile of rotigotine and, in particular, whether its constant delivery system offers significant benefits to the treatment of early and advanced PD. Methods: Source material was identified using a PubMed search for the term 'rotigotine' (up to March 2008). The review focuses only on publications related to the rotigotine indication for PD. Results/conclusion: The rotigotine transdermal patch demonstrates clinical efficacy, alongside a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists. The once-daily patch formulation may favour compliance but, in similarity with the other theoretical advantages of constant drug delivery (for example reduced emergence of motor complications, improved tolerance to peripheral AEs), requires further detailed study.
Fil: Rascol, Olivier. Inserm; Francia
Fil: Perez Lloret, Santiago. Inserm; Francia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay; Argentina
description Background: Rotigotine is a non-ergot dopamine agonist that has been developed as a new transdermal formulation, and is indicated for use in early (USA and Europe) and advanced (Europe only) Parkinson's disease (PD). The potential advantages of the rotigotine patch include immediacy of effect onset as intestinal absorption in unneeded, constant drug delivery, and ease of use via application of a once-daily adhesive patch. An interesting element of this profile is constant drug delivery, which may avoid pulsatile dopaminergic stimulation, which has been postulated to be related to the development of motor complications. Objective: To consider the evidence surrounding the profile of rotigotine and, in particular, whether its constant delivery system offers significant benefits to the treatment of early and advanced PD. Methods: Source material was identified using a PubMed search for the term 'rotigotine' (up to March 2008). The review focuses only on publications related to the rotigotine indication for PD. Results/conclusion: The rotigotine transdermal patch demonstrates clinical efficacy, alongside a tolerability profile that appears to be well within the range of that observed with other non-ergot dopamine agonists. The once-daily patch formulation may favour compliance but, in similarity with the other theoretical advantages of constant drug delivery (for example reduced emergence of motor complications, improved tolerance to peripheral AEs), requires further detailed study.
publishDate 2009
dc.date.none.fl_str_mv 2009-03
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/114178
Rascol, Olivier; Perez Lloret, Santiago; Rotigotine transdermal delivery for the treatment of Parkinson's disease; Informa Healthcare; Expert Opinion on Pharmacotherapy; 10; 4; 3-2009; 677-691
1465-6566
CONICET Digital
CONICET
url http://hdl.handle.net/11336/114178
identifier_str_mv Rascol, Olivier; Perez Lloret, Santiago; Rotigotine transdermal delivery for the treatment of Parkinson's disease; Informa Healthcare; Expert Opinion on Pharmacotherapy; 10; 4; 3-2009; 677-691
1465-6566
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1517/14656560902746041
info:eu-repo/semantics/altIdentifier/doi/10.1517/14656560902746041
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269142847062016
score 13.13397

Publicaciones similares